Stwardnienie Rozsiane

Neuro-Medic oferujemy bezpłatne leczenie stwardnienia rozsianego w ramach NFZ
lub w programach lekowych sponsorowanych przez światowe wiodące firmy farmaceutyczne. Obecnie współpracuje z nami m.in. Teva Pharmaceuticals, Biogen Idec, Hoffman La Roche, Actelion,
Synthon BV, Nuron, Avanir. Nasi pacjenci obecnie leczeni są preparatami interferonu beta, octanem gliatimeru, daclizumabem, ocrelizumabem, laquinimodem i ponesimodem.

Pacjenci zainteresowani bezpłatnym leczeniem w ramach prowadzonych w naszym Ośrodku programów terapeutycznych mogą skorzystać z bezpłatnych wizyt rejestracyjno-konsultacyjnych
po uprzedniej rejestracji telefonicznej tel. : 601-747-130 lub mailowej: neuromedic@op.pl

Do leczenia kwalifikują się pacjenci z rzutowo-remitującą lub pierwotnie postępującą postacią stwardnienia rozsianego.

Nasza oferta skierowana jest także do pacjentów, którzy byli lub są leczeni interferonem beta
w ramach programu NFZ. Jeżeli pomimo leczenia występują rzuty choroby, co świadczy
o braku efektu terapeutycznego interferonu, należy myśleć o zmianie leczenia.

Zajmujemy się także problemem leczenia bólu neuropatycznego w stwardnieniu rozsianym
- choroba zaburza przewodzenie informacji ruchowych i czuciowych wzdłuż włókien nerwowych i oprócz bólu wywołuje takie objawy, jak drętwienie, mrowienie, palenie, pieczenie, czy wrażenie osłabienia kończyn.

 

Lista programów terapeutycznych (badań klinicznych) w stwardnieniu rozsianym wykonywanych przez lekarzy zatrudnionych w Neuro –Medic.

 

A randomized double blind placebo controlled, fixed-flexible dose, parallel group multicenter study to determine the dose and the safety, tolerability and preliminary efficacy of CCI-779 in subject with RRMS (Wyeth) 2003-2004.

A multicenter, randomized, double blind long term extension study to determine the safety, tolerability and preliminary efficacy of CCI-779 in subject with RRMS (Wyeth) 2004-2005.

A randomized, parallel group, placebo controlled, double blind phase III study of Bioferon (interferon beta- 1a) in the treatment of RRMS(BioPartners) 2003-2006.

IMP100434 randomized, double blind placebo-controlled study to compare the effects of different dose regimens of IG iv, 10% treatment on relapses in patients with RRMS(Bayer) 200-2004.

MS-LAQ 5062 /A multinational, multicenter, randomized, double blind, parallel-group, placebo controlled study ,to evaluate the efficacy, tolerability and safety of two doses of Laquinimod orally administrated in relapsing- remitting multiple sclerosis subjects (sponsor TEVA 2005-2006).

 

An active extension of LAQ/5062 study. A multinational, multi-center, randomized, double blind, parallel-group study to evaluate the efficacy, tolerability and safety of two doses (0.3mg and 0.6mg) of Laquinimod, orally administered in relapsing-remitting multiple sclerosis subjects (sponsor TEVA 2005-2006).

A multinational, multicenter, randomized, double blind, parallel-group study , to evaluate the safety, tolerability and efficacy of two doses (0,3 mg and 0,6 mg)of Laquinimod orally administrated in relapsing- remitting multiple sclerosis subjects study LAQ/5063 active double blind phase followed by an open label phase of laquinimod 0,6 mg daily (sponsor TEVA 2006-2007).

An active extension of LAQ/5063-OL study. A multinational, multicenter, randomized study to evaluate the safety, tolerability and efficacy) of open label phase of laquinimod 0,6 mg daily administrated in relapsing- remitting multiple sclerosis subjects (sponsor TEVA od 2008).

MS-LAQ 301 ALLEGRO/A multinational, multicenter, randomized, double-blind, parallel group, placebo controlled study to evaluate the long term safety, tolerability and efficacy of daily oral administration of laquinimod 0,6 mg in subjects with relapsing- remitting multiple sclerosis (sponsor TEVA 2009-2010).

A multinational, multicenter, open label, single-assigment extension of the MS- LAQ-301 (ALLEGRO) study to evaluate the long term safety, tolerability and effect on disease course of daily oral laquinimod 0,6 mg in subjects with relapsing- remitting multiple sclerosis subjects (sponsor TEVA
od 2010).

A phase 2 , double blind, placebo-controlled, randomized,dose-ranging study of multiple subcutaneous injections of human monoclonal antibody to IL-12p40 (CNTO 1275) in subjects with relapsing-remitting multiple sclerosis (sponsor: Centocor Inc. (2005-2007).

International, randomized, multicenter, phase IIIb study in patients with relapsing- remitting multiple sclerosis comparing over a treatment period of 104 weeks:

1.Double blinded safety, tolerability, and efficacy of Betaseron/Betaferon 250 ug (8 MIU) and Betaseron/Betaferon 500 ug (16 MIU), both given subcutaneously every day, and,

2. Rater-blinded safety, tolerability and efficacy of Betasero/Betaferon s.c. every other day with Copaxone 20 mg s.c. once daily (sponsor Schering 2005-2007).

 

Double-blind, placebo-controlled, dose-ranging study to determine the efficacy and safety of BG00012 in subjects with relapsing-remitting multiple sclerosis (sponsor Biogen Idec 2005-2006).

A double blind,placebo controlled multi-center study to evaluate the efficacy and safety of MBP8298 in relapsing-remitting multiple sclerosis.(sponsor BioMS Techn.Corp. 2008-2009).

AC-058B201/Multicenter, randomized, double blind, placebo controlled, parallel-group, dose-finding study to evaluate the efficacy, safety and tolerability of three doses of ACT-128800,an oral S1P1 receptor agonist, administered for 24 weeks in patients with relapsing –remitting multiple sclerosis.(sponsor Actelion Pharm.Ltd od 2010).

A multinational, multicenter, randomized, ,parallel-group study performed in subjects with relapsing –remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of Gliatimer acetate (GA) injection 40 mg administered three times a week compared to placeboin a double-blind design. (sponsor TEVA od 2010.)

Multicenter,randomized,double-blind, parallel group extension to study AC-058B201 to investigate the long –term safety, tolerability, and efficacy of 10,20, and 40 mg/day ACT-128800, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis.(sponsor Actelion Pharm.Ltd od 2010).

Multicenter, double-blind, placebo-controlled, dose- ranging study to determine the safety
and efficacy of Daclizumab HYP (DAC HYP) as a monotherapy treatment in subjects with
relapsing-remitting multiple sclerosis (SELECT) (sponsor Biogen Idec, od 2010).

A double–blind,multicenter, placebo-controlled, extension study to evaluate the safety and efficacy of Daclizumab HYP (DAC HYP) in subjects with relapsing-remitting multiple sclerosis who have completed treatment in study 205MS201 (SELECTION) ( sponsor Biogen Idec, od 2010).

A Multicenter, Open-label, Extension Study to Evaluate the Long term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTED), sponsor Biogen Idec, od 2012

Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study
to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β-1a) in Patients with Relapsing Remitting Multiple Sclerosis (protocol number 205MS301, sponsor Biogen Idec, od 2012

A Multicenter, Single-Arm, Open-Label, Clinical Study to Evaluate the Immunogenicity and Pharmacokinetics of Daclizumab High Yield Process (DAC HYP) Prefilled Syringe Administered
by Subcutaneous Injection in Subjects with Relapsing-Remitting Multiple Sclerosis, Protocol no. 205MS302 , Sponsor Biogen Idec, od 2012

A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study
to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis”,Sponsor F.Hoffman- La Roche, od 2012

Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone®(Teva)
in subjects with relapsing remitting multiple sclerosis followed by an open-label 15 month GTR treatment part evaluating the long-term GTR treatment effects, Sponsor Synton BV od 2012

A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis Sponsor Nuron Biotech Inc, od 2012

Zdjęcie

Kontakt

NEURO-MEDIC
PORADNIA WIELOSPECJALISTYCZNA

40-752 Katowice ul. Medyków 22
tel. 32-252-14-20, fax: 32/204-63-99

40-555 Katowice ul. Rolna 10a
tel/fax: 32/251-20-93
tel. kom: 601-747-130

Kontakt e-mail: neuromedic@op.pl